DK3488007T3 - Skalerbare fremgangsmåder med høj indvinding til fremstilling af højt udbytte rekombinant adeno-associeret viral (raav) vektor og rekombinante adeno-associeret virale (raav) vektorer produceret derved - Google Patents

Skalerbare fremgangsmåder med høj indvinding til fremstilling af højt udbytte rekombinant adeno-associeret viral (raav) vektor og rekombinante adeno-associeret virale (raav) vektorer produceret derved Download PDF

Info

Publication number
DK3488007T3
DK3488007T3 DK17831956.2T DK17831956T DK3488007T3 DK 3488007 T3 DK3488007 T3 DK 3488007T3 DK 17831956 T DK17831956 T DK 17831956T DK 3488007 T3 DK3488007 T3 DK 3488007T3
Authority
DK
Denmark
Prior art keywords
raav
high yield
associated viral
recombinant adeno
scalable
Prior art date
Application number
DK17831956.2T
Other languages
English (en)
Inventor
Guang Qu
Younghoon Oh
Haibo Zhang
Laura Duncan
John Fraser Wright
Yuhuan Wang
Original Assignee
Spark Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60992897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3488007(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Spark Therapeutics Inc filed Critical Spark Therapeutics Inc
Application granted granted Critical
Publication of DK3488007T3 publication Critical patent/DK3488007T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • C12N15/861Adenoviral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02Recovery or purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485Exopeptidases (3.4.11-3.4.19)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472Cysteine endopeptidases (3.4.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14009Tripeptidyl-peptidase I (3.4.14.9)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK17831956.2T 2016-07-21 2017-07-21 Skalerbare fremgangsmåder med høj indvinding til fremstilling af højt udbytte rekombinant adeno-associeret viral (raav) vektor og rekombinante adeno-associeret virale (raav) vektorer produceret derved DK3488007T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662365312P 2016-07-21 2016-07-21
PCT/US2017/043291 WO2018017956A2 (en) 2016-07-21 2017-07-21 Scalable high recovery methods for producing high yield recombinant adeno-associated viral (raav) vector and recombinant adeno-associated viral (raav) vectors produced thereby

Publications (1)

Publication Number Publication Date
DK3488007T3 true DK3488007T3 (da) 2024-02-19

Family

ID=60992897

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17831956.2T DK3488007T3 (da) 2016-07-21 2017-07-21 Skalerbare fremgangsmåder med høj indvinding til fremstilling af højt udbytte rekombinant adeno-associeret viral (raav) vektor og rekombinante adeno-associeret virale (raav) vektorer produceret derved

Country Status (17)

Country Link
US (1) US20190284576A1 (da)
EP (1) EP3488007B1 (da)
JP (1) JP7153009B2 (da)
KR (3) KR20190045174A (da)
CN (1) CN109790549A (da)
AU (1) AU2017299779B2 (da)
CA (1) CA3031095A1 (da)
DK (1) DK3488007T3 (da)
ES (1) ES2972859T3 (da)
FI (1) FI3488007T3 (da)
IL (2) IL301963A (da)
MX (1) MX2019000882A (da)
MY (1) MY194198A (da)
PT (1) PT3488007T (da)
RU (1) RU2768045C2 (da)
SG (1) SG11201900366QA (da)
WO (1) WO2018017956A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
EP3510161A4 (en) 2016-08-23 2020-04-22 Akouos, Inc. COMPOSITIONS AND METHODS FOR TREATING PERSONAL HEARING LOSS IN A PERSON
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
EP3774852A1 (en) 2018-04-03 2021-02-17 Stridebio, Inc. Antibody-evading virus vectors
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
FI3953483T3 (fi) 2019-04-11 2023-11-30 Regenxbio Inc Kokoekskluusiokromatografiamenetelmiä rekombinanttien adenoassosioituneiden viruskoostumusten karakterisoimiseksi
CN110499287B (zh) * 2019-08-30 2021-07-23 博雅干细胞科技有限公司 简易制备胎盘间充质干细胞外泌体的方法
US12611436B2 (en) 2019-10-17 2026-04-28 Sarepta Therapeutics, Inc. AAV transfer cassette
JP2022551739A (ja) 2019-10-17 2022-12-13 ストライドバイオ,インコーポレイテッド ニーマン・ピック病c型の治療のためのアデノ随伴ウイルスベクター
KR102167829B1 (ko) * 2020-02-10 2020-10-20 주식회사 이노테라피 아데노연관바이러스용 안정화제 및 이를 이용한 아데노연관바이러스의 안정화 방법
KR20220157944A (ko) 2020-02-21 2022-11-29 아카우오스, 인크. 인간 대상체에서 비-연령-연관 청각 장애를 치료하기 위한 조성물 및 방법
SI3919613T1 (sl) * 2020-06-05 2024-10-30 Sartorius Bia Separations D.O.O. Izboljšana izolacija adeno-asociiranega virusa za učinkovitejše odstranjevanje kontaminirane dna
AU2021328475A1 (en) 2020-08-19 2023-03-16 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
CN116529389A (zh) * 2020-08-20 2023-08-01 贝克顿迪金森公司 用于从血培养物中分离细菌的血细胞裂解剂
WO2023085382A1 (ja) * 2021-11-12 2023-05-19 Agc株式会社 ウイルスの精製方法
JP2023141423A (ja) * 2022-03-24 2023-10-05 国立大学法人 東京大学 ウイルスの精製方法
WO2026070787A1 (ja) * 2024-09-30 2026-04-02 富士フイルム和光純薬株式会社 脂質二重膜粒子の製造方法及び溶液組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE360683T1 (de) 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
BRPI0511764B8 (pt) * 2004-06-01 2021-05-25 Avigen Inc método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav
GT200600027A (es) * 2005-01-25 2006-08-31 Protectores contra el esfuerzo cortante en la microfiltracion de la cosecha
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CN102257134B (zh) * 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
EP2344634A4 (en) * 2008-09-24 2012-08-29 Medimmune Llc METHODS OF CELL CULTURE, AND PROPAGATION AND PURIFICATION OF VIRUSES
FR2944292B1 (fr) * 2009-04-08 2013-08-23 Sanofi Pasteur Procede de purification du virus rabique
WO2011094198A1 (en) * 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
WO2012057363A1 (ja) * 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
DK2970948T3 (da) * 2013-03-15 2019-04-08 Glaxosmithkline Biologicals Sa Fremgangsmåder til rna-oprensning
CN105612250A (zh) * 2013-10-07 2016-05-25 诺华股份有限公司 经处理的滤器
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
AU2016366560A1 (en) 2015-12-11 2018-06-28 The Trustees Of The University Of Pennsylvania Gene therapy for treating familial hypercholesterolemia

Also Published As

Publication number Publication date
JP2019524101A (ja) 2019-09-05
RU2768045C2 (ru) 2022-03-23
KR20190045174A (ko) 2019-05-02
AU2017299779B2 (en) 2021-12-02
JP7153009B2 (ja) 2022-10-13
MY194198A (en) 2022-11-21
IL264270A (en) 2019-02-28
CN109790549A (zh) 2019-05-21
MX2019000882A (es) 2019-08-12
US20190284576A1 (en) 2019-09-19
FI3488007T3 (fi) 2024-03-19
IL301963A (en) 2023-06-01
KR102695908B1 (ko) 2024-08-14
RU2019104759A3 (da) 2020-11-17
EP3488007A2 (en) 2019-05-29
EP3488007A4 (en) 2020-01-01
BR112019001146A2 (pt) 2019-04-30
WO2018017956A3 (en) 2018-03-08
KR20240126073A (ko) 2024-08-20
KR20220162834A (ko) 2022-12-08
AU2017299779A1 (en) 2019-01-31
WO2018017956A2 (en) 2018-01-25
EP3488007B1 (en) 2023-12-20
SG11201900366QA (en) 2019-02-27
RU2019104759A (ru) 2020-08-21
CA3031095A1 (en) 2018-01-25
ES2972859T3 (es) 2024-06-17
PT3488007T (pt) 2024-03-14
NZ750016A (en) 2025-09-26

Similar Documents

Publication Publication Date Title
DK3488007T3 (da) Skalerbare fremgangsmåder med høj indvinding til fremstilling af højt udbytte rekombinant adeno-associeret viral (raav) vektor og rekombinante adeno-associeret virale (raav) vektorer produceret derved
EP3558393A4 (en) ADENO-ASSOCIATED VIRAL VECTORS
IL277666A (en) Virus vector evasion antibody
IL246588A0 (en) High titer production of adeno-associated virus vectors
IL263801A (en) Novel adeno-associated virus capsid proteins
CL2018002754A1 (es) Proceso de produccion de raav a base de columnas completamente escalable.
EP3645021A4 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
IL277664A (en) Virus vector evasion antibody
DK3356390T3 (da) Fremgangsmåder og sammensætninger til virusvektorer, der undgår antistoffer
DK3390429T3 (da) Modificerede kapsid-proteiner til forbedret afgivelse af parvovirus-vektorer
LT3589730T (lt) Adenoasocijuoto viruso (aav) monofiletinės grupės f vektorius, ir jo panaudojimo būdai
DK3442602T3 (da) Adeno-associeret virusvektors frigørelse af mikrodystrofin til behandling af muskeldystrofi
DK3268024T3 (da) Rekombinante glut1-adeno-associerede virusvektorkonstrukter og relaterede fremgangsmåder til genoprettelse af glut1-ekspression
EP3221456A4 (en) Genome-modified recombinant adeno-associated virus vectors
DK3408382T3 (da) Onkolytiske virale vektorer og anvendelser deraf
DK3889166T3 (da) Rekombinante virale vektorer, der indeholder mindre væsentlige prrsv-proteiner, og fremgangsmåder til fremstilling og anvendelse deraf
DK3684924T5 (da) Ikke-integrerende dna-vektorer til genetisk modifikation af celler
LT3137497T (lt) Aav vektoriai, skirti tinklainės ir cns genų terapijai
HK1245326A1 (zh) 用於生产scaav的组合物和方法
DK3441425T3 (da) Cellulose-aluminium-dispergeret polyethylenharpikskomposit, pellet og formet element ved anvendelse af samme og fremgangsmåde til fremstilling af samme
DK3377618T3 (da) Buffere til stabilisering af lentivirus-præparater
IL286475A (en) Methods for the manufacture of recombinant viral vectors
DK3292210T3 (da) Semikontinuerlig fremgangsmåde til fremstilling af rhamnolipider med højt udbytte og høj titer
IL280840A (en) Production methods for viral vectors
DK3113795T3 (da) Rekombinante virale isfahan-vektorer